ImmuPharma (LON:IMM) Stock Price Up 25.8% – Should You Buy?

Shares of ImmuPharma plc (LON:IMM) were up 25.8% during mid-day trading on Thursday . The stock traded as high as GBX 2.40 ($0.03) and last traded at GBX 2 ($0.03). Approximately 8,864,882 shares were traded during mid-day trading, an increase of 48% from the average daily volume of 5,995,505 shares. The stock had previously closed at GBX 1.59 ($0.02).

ImmuPharma Stock Performance

The firm has a market capitalization of £7.76 million, a P/E ratio of -3.16 and a beta of 1.53. The firm has a 50-day moving average of GBX 2.01 and a 200-day moving average of GBX 2.71.

ImmuPharma (LON:IMM) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.